[1] Vilata J J, Badia X. ESCCRIM group. Effectiveness, satisfaction and compliance with imiquimod in the treatment of external anogenital warts. Int J STD AIDS, 2003, 14:11-17. [2] Bayerl C, Feller G, Goerdt S. Experience in treating molluscum contagiosum in children with imiquimod 5% cream. Br J Dermatol,2003, 149, 66:25-29. [3] Eklind J, Tartler U, Maschke J, et al. Imiquimod to treat different cancers of the epidermis. Dermatol Surg, 2003, 29:890-896. [4] 顾恒,曾凡钦,郭在培,等.咪喹莫特乳膏治疗尖锐湿疣随机、双肓、多中心研究.中华皮肤科杂志,2003,36:501-504. [5] Tchou I, Sabido O, Lambert C, et al. Technique for obtaining highly enriched, quiescent immature Langerhans cells suitable for ex vivo assays. Immunol Lett, 2003, 86:7-14. [6] Mempel M, Voelcker V, Kollisch G, et al. Toll-like receptor expression in human keratinocytes:nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol, 2003, 121:1389-1396. [7] Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol, 1998, 110:734-739. [8] Kono T, Kondo S, Pastore S, et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res, 1994, 13:71-76. |